<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">OJPM</journal-id>
      <journal-title-group>
        <journal-title>Open Journal of Preventive Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2162-2477</issn>
      <publisher>
        <publisher-name>Scientific Research Publishing</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.4236/ojpm.2023.1312021</article-id>
      <article-id pub-id-type="publisher-id">OJPM-129921</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine&amp;Healthcare</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>


          Prevalence of Viral Hepatitis B among Women of Childbearing Age in the Kara Region of Togo in 2022

        </article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Gatibe</surname>
            <given-names>Yendu-Suglpak Gnatou</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Fatoumata</surname>
            <given-names>Binta Tidiane Diallo</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Fifonsi</surname>
            <given-names>Adjidossi Gbeasor-Komlanvi</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Sibabe</surname>
            <given-names>Agoro</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Arnold</surname>
            <given-names>Junior Sadio</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Latame</surname>
            <given-names>Komla Adoli</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Wendpouire</surname>
            <given-names>Ida Carine Zida-Compaore</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Yao</surname>
            <given-names>Rodion Konu</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Martin</surname>
            <given-names>Kouame Tchankoni</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Amegnona</surname>
            <given-names>Agbonon</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Didier</surname>
            <given-names>Koumavi Ekouevi</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff5">
        <addr-line>African Centre for Research in Epidemiology and Public Health (CARESP), Lomé, Togo</addr-line>
      </aff>
      <aff id="aff4">
        <addr-line>Ministry of Health, Public Hygiene and Universal Access to Health Care, Lomé, Togo</addr-line>
      </aff>
      <aff id="aff3">
        <addr-line>Center for Training and Research in Public Health, University of Lomé, Lomé, Togo</addr-line>
      </aff>
      <aff id="aff7">
        <addr-line>Institute of Public Health and Development, University of Bordeaux, Bordeaux, France</addr-line>
      </aff>
      <aff id="aff2">
        <addr-line>Togo Office, World Health Organization (WHO), Lomé, Togo</addr-line>
      </aff>
      <aff id="aff1">
        <addr-line>Department of Public Health, Faculty of Health Sciences, University of Lomé, Lomé, Togo</addr-line>
      </aff>
      <aff id="aff6">
        <addr-line>Laboratory of Pharmacology and Physiology, University of Lomé, Lomé, Togo</addr-line>
      </aff>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>12</month>
        <year>2023</year>
      </pub-date>
      <volume>13</volume>
      <issue>12</issue>
      <fpage>319</fpage>
      <lpage>328</lpage>
      <history>
        <date date-type="received">
          <day>28,</day>
          <month>October</month>
          <year>2023</year>
        </date>
        <date date-type="rev-recd">
          <day>18,</day>
          <month>December</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>21,</day>
          <month>December</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement>
        <copyright-year>2014</copyright-year>
        <license>
          <license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p>
        </license>
      </permissions>
      <abstract>
        <p>


          Introduction: The hepatitis B virus (HBV) is one of the major causes of morbidity and mortality in the world. Few up-to-date data on this disease are available in developing countries, including Togo. The aim of this study was to estimate the prevalence of hepatitis B among women of childbearing age in the Kara region of Togo.
          Methods: A cross-sectional study was carried out from 23 to 25 September 2022 during a fairground campaign. Data were collected using a standardised questionnaire. HBV screening was performed using “SD-BIOLINE HBsAg WB” rapid immunochromatographic tests. HBV prevalence was reported with its 95% confidence interval (CI). Regression analyses were performed to identify factors associated with HBV infection.
          Results: A total of 327 women were enrolled, with a median age of 34 years and an interquartile range of [25 - 43]. Nearly half (49.5%) of the women had had their first sexual intercourse before the age of 18 and 2.1% had at least 2 sexual partners at the time of the survey. The majority (91.7%) had not used a condom the last time they had sex. The prevalence of hepatitis B was 10.4% (95% CI: 7.5 - 14.2]). In multivariable analysis, having had sexual intercourse for the first time after the age of 18 (ORa = 0.17; 95% CI [0.06 - 0.43]; p &lt; 0.001), and secondary (ORa = 0.24; 95% CI [0.09 - 0.61]; p = 0. 003) or university education (ORa = 0.25; 95% CI [0.77 - 0.86]; p = 0.028) were protective factors against HBV infection compared with those who had primary education or had never attended school.
          Conclusion: The results of this study underline the importance of monitoring the prevalence of hepatitis B in women of childbearing age, and of implementing targeted prevention and screening measures to eliminate mother-to-child transmission of HBV.

        </p>
      </abstract>
      <kwd-group>
        <kwd>Hepatitis B Virus</kwd>
        <kwd> Women of Childbearing Age</kwd>
        <kwd> Togo</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>1. Introduction</title>
      <p>
        Hepatitis B is an infectious liver disease characterised by hepatocellular necrosis and caused by a virus belonging to the Hepadnaviridae family [<xref ref-type="bibr" rid="scirp.129921-ref1">1</xref>] . Infection with the hepatitis B virus (HBV) remains a major cause of acute and chronic liver disease, with significant morbidity and mortality worldwide [<xref ref-type="bibr" rid="scirp.129921-ref2">2</xref>] . The risk of chronic infection following exposure to HBV depends on age at the time of infection, with a 90% risk when infection occurs in early childhood and a risk of less than 10% when infection occurs in immunocompetent adolescents and adults [<xref ref-type="bibr" rid="scirp.129921-ref3">3</xref>] . In 2021, the World Health Organisation (WHO) estimates that around 240 million people worldwide will be infected with the hepatitis B virus [<xref ref-type="bibr" rid="scirp.129921-ref4">4</xref>] , but only 11% of people living with viral hepatitis know their serological status [<xref ref-type="bibr" rid="scirp.129921-ref5">5</xref>] . HBV infection is more widespread than other types of hepatitis, with 1.5 million new infections each year and 887,000 deaths due to chronic HBV infection [<xref ref-type="bibr" rid="scirp.129921-ref2">2</xref>] . Sub-Saharan Africa is one of the most endemic regions in Africa, with hepatitis B prevalence estimated at around 8% [<xref ref-type="bibr" rid="scirp.129921-ref6">6</xref>] . The prevalence of HBV is particularly high in regions where HIV is endemic [<xref ref-type="bibr" rid="scirp.129921-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.129921-ref8">8</xref>] . Hepatitis B is a viral infection that can be transmitted sexually, making it a sexually transmitted infection (STI) [<xref ref-type="bibr" rid="scirp.129921-ref9">9</xref>] . In women, hepatitis B is a health problem because of its implications for reproductive and general health [<xref ref-type="bibr" rid="scirp.129921-ref9">9</xref>] . HBV infection in women presents specific risks, in particular vertical transmission from mother to child during pregnancy or childbirth [<xref ref-type="bibr" rid="scirp.129921-ref10">10</xref>] . Transmission of HBV in women occurs mainly through direct contact with the blood or semen of an infected person [<xref ref-type="bibr" rid="scirp.129921-ref11">11</xref>] . Risky behaviour such as unprotected sex and sharing contaminated needles or objects also increase the risk of infection with the hepatitis B virus [<xref ref-type="bibr" rid="scirp.129921-ref12">12</xref>] . Preventing hepatitis B in women is based on essential measures such as promoting the use of condoms during sexual relations, early screening to ensure that infected women receive appropriate care, and vaccination against hepatitis B [<xref ref-type="bibr" rid="scirp.129921-ref11">11</xref>] . In view of the consequences of HBV infection, Togo’s public health authorities have been gradually introducing measures to prevent hepatitis B since 2008, with the introduction of the hepatitis B vaccine as part of the Expanded Programme on Immunisation (EPI) [<xref ref-type="bibr" rid="scirp.129921-ref13">13</xref>] . In Togo and the Kara region, few studies of the prevalence of hepatitis B in women of childbearing age have been carried out [<xref ref-type="bibr" rid="scirp.129921-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.129921-ref15">15</xref>] .
      </p>
      <p>
        A study carried out in 2016 in Lom&#233; among the general population showed that belonging to the Kaby&#232; ethnic group (population of the Kara region) was a risk factor associated with the carriage of HBsAg [<xref ref-type="bibr" rid="scirp.129921-ref14">14</xref>] . The lack of up-to-date data on the prevalence of hepatitis B means that we have no real idea of the epidemiological situation, which could guide public health actions (prevention, screening and treatment) and thus help to reduce the transmission and control of this disease. In order to obtain factual, up-to-date data on hepatitis B, we conducted this study with the aim of estimating the prevalence of hepatitis B and describing its associated factors among women of childbearing age in the Kara region of Togo in 2022.
      </p>
    </sec>
    <sec id="s2">
      <title>2. Methods</title>
      <sec id="s2_1">
        <title>2.1. Study Design and Period</title>
        <p>A descriptive and analytical cross-sectional study was carried out from 23 to 25 September 2022 in the Kara region in northern Togo, 420 km from Lom&#233;, the capital of Togo.</p>
      </sec>
      <sec id="s2_2">
        <title>2.2. Study Population</title>
        <p>The study population consisted of women of childbearing age in the Kara region. The eligibility criteria included: 1) being between the ages of 18 and 45, 2) having resided in the Kara region in the 12 months leading up to the survey, and 3) providing oral consent for enrollment in the study.</p>
        <p>Given the context of a fairground campaign, an accidental non-probability sampling method was used to recruit the women.</p>
      </sec>
      <sec id="s2_3">
        <title>2.3. Sample Size</title>
        <p>
          The number of subjects required was calculated on the basis of estimates of the prevalence of HBsAg infection among women in Togo, estimated at 10% [<xref ref-type="bibr" rid="scirp.129921-ref15">15</xref>] . For this estimate to be accurate to 1%, i.e., a 95% confidence interval for HBsAg prevalence of between 8% and 12%, at least 384 subjects would need to be included.
        </p>
      </sec>
      <sec id="s2_4">
        <title>2.4. Data Collection</title>
        <p>The data was collected using a standardised questionnaire. The questionnaire was developed by an epidemiologist and a biologist and administered face-to-face by nurses who had been trained beforehand.</p>
        <p>The average time taken to complete the questionnaire was five minutes. The questionnaire included items on socio-demographic characteristics, sexuality, gynaeco-obstetric history and condom use.</p>
        <p>The questionnaire was pre-tested with 10 women to reformulate questions that were difficult to understand. The women who took part in the pre-test did not take part in the final survey.</p>
      </sec>
      <sec id="s2_5">
        <title>2.5. Study Procedures</title>
        <p>A fairground campaign was organised by the Kara Regional Health Department. A space was set up to welcome the participants and to carry out the hepatitis B counselling and screening activities effectively. Only volunteers were enrolled in the study.</p>
      </sec>
      <sec id="s2_6">
        <title>2.6. Hepatitis B Screening (HBsAg)</title>
        <p>On-site screening for hepatitis B was carried out by laboratory technicians who had been trained beforehand. Capillary blood samples were taken from the fingertips and tested using the “SD-BIOLINE HBsAg WB” rapid immunochromatographic tests. Pre- and post-test advice on the hepatitis B virus was given, and the serological status was communicated to the participants 2 to 3 hours after the sample was taken. Once the results were available, the healthcare professionals explained the results to the participants. In the event of a positive result, appropriate medical advice was provided, and those concerned were referred to healthcare facilities for full medical follow-up and treatment if necessary. In the event of a negative result, participants were urged to take preventive measures such as vaccination (after additional tests had been carried out, including hepatitis B markers) and the use of safe sex practices to avoid future exposure to the hepatitis B virus.</p>
      </sec>
      <sec id="s2_7">
        <title>2.7. Statistical Analysis</title>
        <p>After collection, the data was entered and saved on a database developed using EPIData (French version 3.1). The data were analysed using R &#169; version 4.2.1 software. Quantitative variables were presented as medians with their interquartile ranges (IQR), and categorical variables were presented as numbers and proportions. The prevalence of hepatitis B was estimated with its 95% confidence interval. Univariate and multivariate logistic regression analyses were performed to identify factors associated with HBV infection. The significance threshold for statistical tests was set at 5%.</p>
      </sec>
      <sec id="s2_8">
        <title>2.8. Ethical Considerations</title>
        <p>This study received favourable opinions from the Bioethics Committee for Health Research (opinion number 02/2022/CBRS dated 18 January 2022) and from the Regional Director of Health in Kara. The objectives of the study were explained to the participants. They were informed that their participation was voluntary and that they were free, without justification, to withdraw at any time without any negative consequences for them. They were given the necessary time to reflect before deciding whether or not to take part in the study. Verbal consent was obtained from each participant prior to inclusion. The confidentiality of the data collected was guaranteed by using a unique identifier.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>3. Results</title>
      <sec id="s3_1">
        <title>3.1. Socio-Demographic Characteristics</title>
        <p>
          A total of 327 women with a median age of 34 years, IIQ [25 - 43] were enrolled. The majority (89.0%) were married and only 19.3% had a university education. The socio-demographic characteristics of the participants are summarised in <xref ref-type="table" rid="table1">Table 1</xref>.
        </p>
      </sec>
      <sec id="s3_2">
        <title>3.2. Sexuality. Gynaeco-Obstetrical History and Condom Use</title>
        <p>Almost half (49.5%) of the women had had their first sexual intercourse before the age of 18 and 2.1% had had 2 or more sexual partners at the time of the survey.</p>
        <p>The majority (91.7%) had not used a condom the last time they had sex.</p>
        <p>
          <xref ref-type="table" rid="table2">Table 2</xref> describes sexuality. Participants’ obstetric history and condom use at last intercourse.
        </p>
      </sec>
      <sec id="s3_3">
        <title>3.3. Pr&#233;valence</title>
        <p>The prevalence of hepatitis B was 10.4% (95% CI: [7.5 - 14.2]).</p>
      </sec>
      <sec id="s3_4">
        <title>3.4. Factors Associated with Viral Hepatitis B Infection</title>
        <p>In multivariable analysis, having had sexual intercourse for the first time after the age of 18 (ORa = 0.17; 95% CI [0.06 - 0.43]; p &lt; 0.001) and a secondary (ORa = 0.24; 95% CI [0.09 - 0.61]; p = 0.003) or university (ORa = 0.25; 95% CI [0.77 - 0.86]; p = 0.028) level of education were protective factors against HBV infection.</p>
        <p>
          The factors associated with viral hepatitis B infection are summarised in <xref ref-type="table" rid="table3">Table 3</xref>.
        </p>
        <table-wrap id="table1" >
          <label>
            <xref ref-type="table" rid="table1">Table 1</xref>
          </label>
          <caption>
            <title> Socio-demographic characteristics of participants (n = 327)</title>
          </caption>
          </table-wrap>
        </sec>
      </sec>
    </body>
            
          <back>
            <ref-list>
              <title>References</title>
              <ref id="scirp.129921-ref1">
                <label>1</label>
                <mixed-citation publication-type="other" xlink:type="simple">WHO: World Health Organization (2008) Guidelines Approved by the Guidelines Review Committee.</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref2">
                <label>2</label>
                <mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2021) Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021.https://www.who.int/publications-detail-redirect/9789240027077</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref3">
                <label>3</label>
                <mixed-citation publication-type="other" xlink:type="simple">Edmunds, W.J., Medley, G.F., Nokes, D.J., Hall, A.J. and Whittle, H.C. (1997) The Influence of Age on the Development of the Hepatitis B Carrier State. Proceedings of the Royal Society of London Series B: Biological Sciences, 253, 197-201. https://doi.org/10.1098/rspb.1993.0102</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref4">
                <label>4</label>
                <mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2016) Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards Ending Viral Hepatitis. https://www.who.int/publications-detail-redirect/WHO-HIV-2016.06</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref5">
                <label>5</label>
                <mixed-citation publication-type="other" xlink:type="simple">Find the Missing Millions Advocacy Resource. https://www.worldhepatitisalliance.org/missing-millions/</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref6">
                <label>6</label>
                <mixed-citation publication-type="other" xlink:type="simple">Kafeero, H.M., Ndagire, D., Ocama, P., Kudamba, A., Walusansa, A. and Sendagire, H. (2021) Prevalence and Predictors of Hepatitis B Virus (HBV) Infection in East Africa: Evidence from a Systematic Review and Meta-Analysis of Epidemiological Studies Published from 2005 to 2020. Archives of Public Health, 79, Article No. 167. https://doi.org/10.1186/s13690-021-00686-1</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref7">
                <label>7</label>
                <mixed-citation publication-type="other" xlink:type="simple">Coffie, P.A., Patassi, A., Doumbia, A., Bado, G., Messou, E., Minga, A., et al. (2017) Changes in Viral Hepatitis B Screening Practices over Time in West African HIV Clinics. Médecine et Maladies Infectieuses, 47, 394-400. https://doi.org/10.1016/j.medmal.2017.04.011</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref8">
                <label>8</label>
                <mixed-citation publication-type="other" xlink:type="simple">Lavanchy, D. (2004) Hepatitis B Virus Epidemiology, Disease Burden, Treatment, and Current and Emerging Prevention and Control Measures. Journal of Viral Hepatitis, 11, 97-107. https://doi.org/10.1046/j.1365-2893.2003.00487.x</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref9">
                <label>9</label>
                <mixed-citation publication-type="other" xlink:type="simple">McMahon, B.J. (2009) The Natural History of Chronic Hepatitis B Virus Infection. Hepatology, 49, S45-S55. https://doi.org/10.1002/hep.22898</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref10">
                <label>10</label>
                <mixed-citation publication-type="other" xlink:type="simple">Beasley, R.P., Trepo, C., Stevens, C.E. and Szmuness, W. (1977) The e Antigen and Vertical Transmission of Hepatitis B Surface Antigen. American Journal of Epidemiology, 105, 94-98. https://doi.org/10.1093/oxfordjournals.aje.a112370</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref11">
                <label>11</label>
                <mixed-citation publication-type="other" xlink:type="simple">Kao, J.H. (2015) Hepatitis B Vaccination and Prevention of Hepatocellular Carcinoma. Best Practice &amp; Research Clinical Gastroenterology, 29, 907-917. https://doi.org/10.1016/j.bpg.2015.09.011</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref12">
                <label>12</label>
                <mixed-citation publication-type="other" xlink:type="simple">Omeje, K.N., Ibekwe, R.C., Ojukwu, J.O., Una, A.F. and Ibe, B.C. (2017) Risk Factors for Hepatitis B Surface Antigenaemia among Secondary School Students in Abakaliki, South Eastern Nigeria. Nigerian Journal of Paediatrics, 44, 14-21. https://doi.org/10.4314/njp.v44i1.3</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref13">
                <label>13</label>
                <mixed-citation publication-type="other" xlink:type="simple">Ministère de la Santé du Togo (2010) Programme Elargi de Vaccination du Togo. Rapport d’activités de l’année 2009.</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref14">
                <label>14</label>
                <mixed-citation publication-type="other" xlink:type="simple">Halatoko, W.A., Patassi, A., Yanogo, P., Banla, L.I., Koba, A., Issa, Z., et al. (2019) Risk Factors of Hepatitis B Virus Surface Antigen Carriage and Serological Profile of HBsAg Carriers in Lomé Togo, 2016. BMC Public Health, 19, Article No. 32. https://doi.org/10.1186/s12889-018-6320-x</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref15">
                <label>15</label>
                <mixed-citation publication-type="other" xlink:type="simple">Ekouevi, D.K., Larrouy, L., Gbeasor-Komlanvi, F.A., Mackiewicz, V., Tchankoni, M.K., Bitty-Anderson, A.M., et al. (2020) Prevalence of Hepatitis B among Childbearing Women and Infant Born to HBV-Positive Mothers in Togo. BMC Infectious Diseases, 20, Article No. 839. https://doi.org/10.1186/s12879-020-05574-7</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref16">
                <label>16</label>
                <mixed-citation publication-type="other" xlink:type="simple">Antuamwine, B.B., Herchel, E.D. and Bawa, E.M. (2022) Comparative Prevalence of Hepatitis B Virus Infection among Pregnant Women Accessing Free Maternal Care in a Tertiary Hospital in Ghana. PLOS ONE, 17, e0263651. https://doi.org/10.1371/journal.pone.0263651</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref17">
                <label>17</label>
                <mixed-citation publication-type="other" xlink:type="simple">Olakunde, B.O., Adeyinka, D.A., Olakunde, O.A., Uthman, O.A., Bada, F.O., Nartey, Y.A., et al. (2021) A Systematic Review and Meta-Analysis of the Prevalence of Hepatitis B Virus Infection among Pregnant Women in Nigeria. PLOS ONE, 16, e0259218. https://doi.org/10.1371/journal.pone.0259218</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref18">
                <label>18</label>
                <mixed-citation publication-type="other" xlink:type="simple">Ekouevi, D.K., Thomas, A., Sewu, D., Lawson-Ananissoh, L., Tchounga, B., Salou, M., et al. (2017) Prevalence of Hepatitis B among Students from the University of Lomé, Togo in 2015. Open Journal of Epidemiology, 7, 262-272. https://doi.org/10.4236/ojepi.2017.73020</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref19">
                <label>19</label>
                <mixed-citation publication-type="other" xlink:type="simple">Banla, A.K., Gani, K.T., Halatoko, W.A., et al. (2015) Prevalence of the Surface Antigen of Hepatitis B Virus among Youth Aged 15 to 24 in TOGO in 2010. Journal of Infectious Diseases &amp; Therapy, 3, Article ID: 1000238. http://www.esciencecentral.org/journals/prevalence-of-the-surface-antigen-of-hepatitis-b-virus-among-youth-aged-15-to-24-in-togo-in-2010-2090-7214-1000238.php?aid=61745 https://doi.org/10.4172/2332-0877.1000238</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref20">
                <label>20</label>
                <mixed-citation publication-type="other" xlink:type="simple">Stevens, C.J., Gillman, A.S., Gardiner, C.K., Montanaro, E.A., Bryan, A.D. and Conner, M. (2019) Feel Good Now or Regret It Later? The Respective Roles of Affective Attitudes and Anticipated Affective Reactions for Explaining Health-Promoting and Health Risk Behavioral Intentions. Journal of Applied Social Psychology, 49, 331-348. https://doi.org/10.1111/jasp.12584</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref21">
                <label>21</label>
                <mixed-citation publication-type="other" xlink:type="simple">Mawouma, A.R.N., Djoulatou, A.H., Komnang, E.O. and Kimessoukie, E.O. (2022) Facteurs associés à l’infection de l’hépatite B chez les femmes enceintes dans les formations sanitaires du district de santé de Mokolo/Région de l’Extr&amp;ecirc;me-Nord Cameroun. The Pan African Medical Journal, 41, Article 61.</mixed-citation>
              </ref>
              <ref id="scirp.129921-ref22">
                <label>22</label>
                <mixed-citation publication-type="other" xlink:type="simple">Martinson, F.E.A., Weigle, K.A., Royce, R.A., Weber, D.J., Suchindran, C.M. and Lemon, S.M. (1998) Risk Factors for Horizontal Transmission of Hepatitis B Virus in a Rural District in Ghana. American Journal of Epidemiology, 147, 478-487. https://doi.org/10.1093/oxfordjournals.aje.a009474</mixed-citation>
              </ref>
            </ref-list>
          </back>
</article>